OncologyTube Professional - Patients Click Here
Gastrointestinal-Cancer-Meeting
71,002 video views
Loading........
Description: Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at the 2018 Gastrointestinal Cancers Symposium.
02:36
Masatoshi Kudo, MD from Kindai University, Japan discusses TACTICS trial demonstrates benefit with TACE plus Sorafenib in unresectable HCC at the 2018 Gastrointestina​l Cancers Symposium.
01:39
Masatoshi Kudo, MD from Kindai University, Japan discusses TACE new cancer region is not failure and TACE + Sorafenib should be continued even after new cancer at the 2018 Gastrointestina​l Cancers Symposium.
00:44
Masatoshi Kudo, MD from Kindai University, Japan discusses TACE + Sorafenib may change standard in HCC and if overall survival data is positive then standard of care will change at the 2018 Gastrointestina​l Cancers Symposium.
00:54
Cathy Eng, MD, FACP GASTROINTESTINA​L MEDICAL ONCOLOGY - MD Anderson discusses the Regorafenib Dose Optimization Study (ReDOS) and how a Weekly escalation Regorafenib 80 to 160 mg-day superior to start dose of 160 mg-day. Recorded at ASCO GI 2018.
01:04
Cathy Eng, MD, FACP GASTROINTESTINA​L MEDICAL ONCOLOGY - MD Anderson discusses the combination of Cobimetinib & Atezolizumab in Metastatic Colorectal Cancer with an 8% Response Rate with an Overall Survival of 13-14 months. Recorded at ASCO GI 2018.
00:55
Cathy Eng, MD, FACP GASTROINTESTINA​L MEDICAL ONCOLOGY - MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded at ASCO GI 2018.
00:56
Cathy Eng, MD, FACP GASTROINTESTINA​L MEDICAL ONCOLOGY - MD Anderson discusses Checking for CEA in Metastatic Anal Cancer and how it may Benefit as a Biologic Marker in Anal Cancer. This was recorded at ASCO GI 2018.
01:10
Soulen - Who Should Get PRRT Weighing Cumulative Toxicity Key to PRRT Treatment Michael C. Soulen, MD of the University of Pennsylvania answers the question "Who Should Get PRRT?". He summarizes that you must weigh cumulative toxicity which may be key to PRRT (Peptide Receptor Radionuclide Therapy) treatment from ASCO GI 2018.
01:04
Michael C. Soulen, MD of the University of Pennsylvania discusses primary resection of tumor in the gut and how there is evidence that there is no survival difference between resected and non-resected from ASCO GI 2018.
01:35
Michael C. Soulen, MD of the University of Pennsylvania discusses that peptide receptor radionuclide therapy US approval expected early 2018 from ASCO GI 2018.

About Gastrointestinal-Cancer-Meeting


Links
Channel Url: